Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.
about
Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the futureEfficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria.The effect of an exercise intervention on aerobic fitness, strength and quality of life in children with haemophilia (ACTRN012605000224628).Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia.Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients.Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Need for Prophylactic Treatment in Adult Haemophilia A PatientsA modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.Outcome measures monitoring physical function in children with haemophilia: a systematic review.Outcome measures in haemophilia: more than just factor levels.Quality of life assessment in haemophilia.Treatment of hemophilia: a review of current advances and ongoing issuesManagement of haemophilia and its complications in developing countries.Optimizing factor prophylaxis for the haemophilia population: where do we stand?Management of chronic synovitis in patients with hemophilia: with special reference to developing countries.Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy.Prophylaxis in adults with haemophilia.Scoring haemophilic arthropathy on X-rays: improving inter- and intra-observer reliability and agreement using a consensus atlasOptimizing outcomes for patients with severe haemophilia A.Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea.Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970sPrimary prophylaxis in children with haemophilia.Novel drugs to treat hemophilia.Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia.Joint protection in haemophilia.Models of prophylaxis.Hemophilia and prophylaxis.The burden of bleeding in haemophilia: is one bleed too many?Considerations in individualizing prophylaxis in patients with haemophilia A.Factor VIII therapy for hemophilia A: current and future issues.Methods for individualising factor VIII dosing in prophylaxis.Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Individualizing prophylaxis in hemophilia: a review.Personalized prophylaxis.Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score.Evaluating outcome of prophylaxis in haemophilia: objective and self-reported instruments should be combined.Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.Endodontic management of a haemophilic patient- a clinical perspectiveLong-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age-matched Danish and Russian patients.
P2860
Q26853631-E76633C4-C365-4EB8-9D33-4E385FA293B4Q31098999-8C7B8277-B478-42B9-B2DC-F8874E741060Q33245039-D46553EC-2CEE-4301-8FF7-9C332EE59DB5Q33346945-2E09F29E-BCA3-478B-B578-CEDCBB5F5D2BQ33634745-7F7BA699-C88C-4289-93EA-2E8C55BFAD7AQ33715399-300BABC1-BA86-4456-99AC-0AD55105C9DDQ34139334-84ACBF0B-82FD-4614-9CF0-0F0A8754514CQ34890523-6B8B9E9E-FF4F-493A-A653-9F2236EFAA70Q35046841-7B52BE61-C3F8-4275-AB66-4DDE768CCFB2Q35676998-2261C268-17DD-4491-86EE-2355AA623EAAQ35677000-A9A0631C-D273-4493-A012-A7AA4672FC04Q35683781-2980240A-E02D-41DA-9EED-957204803F11Q35848322-4E4DDFF6-D75B-4668-963A-EDE7649A8D19Q35915686-AB0C0433-F371-4968-B2DC-A109CDCE16DBQ36330376-C4C2E4A3-3FFC-42BE-BEC4-CFCA7B77F82CQ36473108-316A254F-38FA-4635-9B9A-9F20BF988C46Q36904925-69987EE0-3D5D-426E-B308-CFFC8606F3FCQ36908311-0CD0BD40-1B36-44F4-90D9-4CEC56684791Q36932769-F9574CDF-E360-44DE-9717-7182FA13B0FEQ37057618-99B1CDA6-444E-4FC2-9FCE-4BF27C29AB06Q37059203-6F863C0F-7618-48DE-B4A9-4FEC5C9D560AQ37098836-F89CC942-3CE6-4BA4-8AE8-06AED8F924EDQ37119644-95ADDF01-B400-4980-BB8D-818BFD7004B2Q37775029-8CEA8050-E66C-41A5-9E2F-6E1E1E07FFE1Q37845930-3DEA7A07-BCA2-4955-87F7-D7429B193AEAQ37912258-1DBDD3A2-D11C-43C1-BC09-F8A49190E073Q38020979-385A681B-5D25-404D-9CD1-D9E09E94A4D7Q38056467-15FCD8C4-5327-4376-9109-E4D563D374DFQ38182702-F4A1C62A-8E16-4C17-9A3C-77A790825160Q38203021-15B00CF6-B414-4338-800B-F4667EE2E40BQ38203350-7A94650D-8A56-4411-8655-1176CE4D9759Q38222572-7CFDEEED-DE74-4E39-BFAF-157E04917334Q38227605-FBD31244-1FBB-4386-B28B-C91775BEF1C9Q38323857-D0583461-F291-4B3B-8FB6-5843DECDA7C1Q39596251-2CE666B3-0E92-4278-B790-8D476D610509Q39834857-349C8DE0-6808-451F-AC4D-EF85CCB91C56Q40013630-DF1100F4-ABF3-4E43-8904-BDA6108D5ABCQ41591597-10BBE01C-8BDC-420E-9695-BECD8BA48EA1Q41843328-E11DE797-6EB2-4FC4-ACC8-47A6DF06EB02Q44460074-B72A0C27-2ABC-442B-A820-19320A5BC99E
P2860
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Prophylactic treatment for sev ...... e-dose to a high-dose regimen.
@en
Prophylactic treatment for sev ...... e-dose to a high-dose regimen.
@nl
type
label
Prophylactic treatment for sev ...... e-dose to a high-dose regimen.
@en
Prophylactic treatment for sev ...... e-dose to a high-dose regimen.
@nl
prefLabel
Prophylactic treatment for sev ...... e-dose to a high-dose regimen.
@en
Prophylactic treatment for sev ...... e-dose to a high-dose regimen.
@nl
P2093
P2860
P1433
P1476
Prophylactic treatment for sev ...... te-dose to a high-dose regimen
@en
P2093
D E Grobbee
E Berntorp
H M van den Berg
J Astermark
P2860
P304
P356
10.1046/J.1365-2516.2002.00694.X
P577
2002-11-01T00:00:00Z